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Purpose: To identify the causative mutation in a canine cone-rod dystrophy (crd3) that segregates as an adult onset disorder
in the Glen of Imaal Terrier breed of dog.
Methods: Glen of Imaal Terriers were ascertained for crd3 phenotype by clinical ophthalmoscopic examination, and in
selected cases by electroretinography. Blood samples from affected cases and non-affected controls were collected and
used, after DNA extraction, to undertake a genome-wide association study using Affymetrix Version 2 Canine single
nucleotide polymorphism chips and 250K Sty Assay protocol. Positional candidate gene analysis was undertaken for
genes identified within the peak-association signal region. Retinal morphology of selected crd3-affected dogs was
evaluated by light and electron microscopy.
Results: A peak association signal exceeding genome-wide significance was identified on canine chromosome 16.
Evaluation of genes in this region suggested A Disintegrin And Metalloprotease domain, family member 9 (ADAM9),
identified concurrently elsewhere as the cause of human cone-rod dystrophy 9 (CORD9), as a strong positional candidate
for canine crd3. Sequence analysis identified a large genomic deletion (over 20 kb) that removed exons 15 and 16 from
the ADAM9 transcript, introduced a premature stop, and would remove critical domains from the encoded protein. Light
and electron microscopy established that, as in ADAM9 knockout mice, the primary lesion in crd3 appears to be a failure
of the apical microvilli of the retinal pigment epithelium to appropriately invest photoreceptor outer segments. By
electroretinography, retinal function appears normal in very young crd3-affected dogs, but by 15 months of age, cone
dysfunction is present. Subsequently, both rod and cone function degenerate.
Conclusions: Identification of this ADAM9 deletion in crd3-affected dogs establishes this canine disease as orthologous
to CORD9 in humans, and offers opportunities for further characterization of the disease process, and potential for genetic
therapeutic intervention.
Cone-rod  dystrophies  are  severe  hereditary  retinal
diseases characterized by primary dysfunction and loss of
cone photoreceptors accompanying or preceding that of rods.
The typical age of clinical onset in affected humans ranges
from early to late adulthood; autosomal dominant, recessive,
and X-linked forms of the disease occur. Multiple mapped
human loci are recognized, including over a dozen causative
genes (RETNET). A clinically similar disorder, termed canine
cone-rod dystrophy 3 (crd3), segregates in the Irish Glen of
Imaal Terrier (GIT) breed of dog as an adult onset trait of
previously undetermined mode of inheritance. This disease
becomes  evident  ophthalmoscopically  in  affected  dogs  as
young as 3 years of age, and progresses to end-stage retinal
degeneration  over  several  years.  Concomitantly,  the  dogs
develop  visual  problems;  these  usually  manifest  first  as
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difficulties avoiding obstacles in dim light, and worsen over
several  years  to  apparent  total  blindness.  Its  mode  of
inheritance  has  been  difficult  to  establish  from  natural
populations,  because  of  the  multiple  inbreeding  loops  in
natural  pedigrees.  Previous  candidate  gene  studies  have
excluded unc-119 homolog (C. elegans) (UNC119 [HGR4]),
cone-rod  homeobox  (CRX),  peripherin  2,  retinal
degeneration,  slow  (PRPH2),  interphotoreceptor  matrix
proteoglycan  1  (IMPG-1),  tissue  inhibitor  of
metalloproteinase  3  (TIMP3),  and  retinitis  pigmentosa
GTPase  regulator  interacting  protein  (RPGRIP1)  as  the
causative loci (unpublished data).
The GIT is a numerically small breed originating from
the Wicklow Mountains region of Ireland. Although the breed
has been known internationally since the 19th century, and
was  first  registered  in  1934,  the  present-day  population
derives from a very small number of founders from the 1970s.
It is thus a genetic isolate, with a small gene pool, significant
inbreeding,  and  pedigrees  with  multiply  overlapping
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1549generations.  This  population  structure  predicts  extensive
linkage disequilibrium flanking the mutation site, and creates
an ideal opportunity to map the causative locus by a genome-
wide association study (GWAS), as has been demonstrated
and exploited for other canine traits [1–8].
The present study reports results of a GWAS that found
significant  association  to  crd3  on  canine  chromosome  16
(CFA16), and led to identification of a deletion mutation in
the canine ADAM9 gene that cosegregates with the disease.
The  mutation  removes  approximately  23  kb  of  genomic
sequence,  including  exons  15  and  16,  and  results  in  a
premature  stop  codon  in  exon  17.  The  mutant  protein
translated from this transcript is predicted to be truncated,
lacking the last 287 amino acids of the C-terminus, part of the
cysteine-rich domain, the complete epidermal growth factor
(EGF)-like  domain,  the  transmembrane  domain,  and  the
cytoplasmic tail. The association of this deletion mutation in
canine ADAM9 with crd3 establishes that this canine disease
is orthologous to human CORD9 [9].
METHODS
Animal  use:  All  procedures  involving  animal  care  were
conducted in accordance with the guidelines of the Institute
for Laboratory Animal Research (Guide for the Care and Use
of Laboratory Animals) and the US Public Health Service
(Public Health Service Policy on Humane Care and Use of
Laboratory Animals).
Sample collection: Blood was collected for DNA extraction
from  a)  privately  owned  crd3-affected  and  non-affected
purebred GIT dogs; b) mixed breed dogs derived from GIT
founders and maintained as a study colony as part of an NIH-
sponsored project (EY006855) at the Retinal Disease Studies
Facility  (RDSF)  in  Kennett  Square,  PA;  and  c)  from  80
privately owned pedigreed dogs from breeds not known to
segregate crd3 (Table 1).
Phenotypic evaluation of study dogs:
Clinical diagnosis—Diagnosis of crd3 phenotype was
based  on  ophthalmoscopic  examination.  In  selected  cases
electroretinography  was  undertaken  either  to  confirm  the
diagnosis, or to establish diagnosis before ophthalmoscopic
evidence  of  disease,  using  methods  described  previously
[10].
Morphologic evaluation—From selected colony dogs,
eyes  were  enucleated  post  mortem  and  processed  for
morphologic  evaluation  using  a  triple-fixative  protocol,
essentially  as  described  previously  [11,12].  In  brief,
enucleated  eyes  were  slit  (5–10  mm)  at  the  equator,  and
initially fixed whole by immersion in 3% glutaraldehyde-2%
formaldehyde in 0.1 M Na cacodylate buffer (pH 7.2–7.4) at
room temperature; after 5–10 min the anterior segment was
removed by dissection with fine scissors, the vitreous was
gently removed from the eyecup, and the eyecup was replaced
into the same fixative, on ice. Eyecups remained in the first
fixative at 4 °C for a minimum of 45 min and up to 24 h. Then
the eyecup was transferred to the second fixative (freshly
made 2% glutaraldehyde-1% osmium tetroxide, in 0.1 M Na
cacodylate buffer, pH 7.2–7.4) on ice, for 45 min to 1 h. Next,
the  posterior  segment  was  trimmed  into  four  quadrants
TABLE 1. BREEDS TESTED FOR THE PRESENCE OF ADAM9 CRD3-MUTATION.
Breed number Breed Number tested
1 American Cocker Spaniel 5
2 American Eskimo 6
3 Australian Cattle Dog 5
4 Border Collie 5
5 Chesapeake Bay Retriever 5
6 Chinese Crested 5
7 Elkhound 3
8 English Springer Spaniel 5
9 Entlebucher Mountain Dog 5
10 Golden Retriever 5
11 Italian Greyhound 5
12 Labrador Retriever 5
13 Nova Scotia Duck Tolling 5
14 Siberian Husky 5
15 Tibetan Terrier 5
16 Portuguese Water Dog 6
Total   80
All dogs were homozygous normal.
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1550extending  from  the  optic  disc  to  the  ora  serrata,  and  the
trimmed  quadrants  were  separately  placed  into  the  third
fixative (2% osmium tetroxide in 0.1 M Na cacodylate buffer)
for 1 h at 4 °C, or on ice. The quadrants were then dehydrated
in increasing concentrations of ethanol and embedded in an
epoxy resin (PolyBed 812; Polyscience, Warrington, PA),
sectioned  at  1  µm  (Supercut  2065  microtome;  Leica,
Deerfield, IL), stained with azure II (Sigma, Atlanta, GA) and
methylene blue (Electron Microscopy Services, Hatfield, PA)
and counterstained with paraphenylenediamine (Sigma). For
each dog, 1 μm sections extending continuously from the optic
disc  to  the  ora  serrata  of  superior,  inferior,  and  temporal
meridians were evaluated using a light microscope.
From selected epoxy embedded blocks, after an area of
interest was first determined by light microscopy, a 1–1.5 mm
square  pyramid  was  trimmed;  ultrathin  sections
(approximately 60 nm) were cut with a 3 mm diamond knife
on a Reichert Ultracut 701701 ultra microtome (Reichert-
LABTEC, München, Austria) and floated onto nickel thin bar
grids. The grids were then stained for 20 min with aqueous
2% uranyl acetate, washed with degassed mQ water (Milli-Q-
Synthesis  A  10  System,  Model=ZMQP6VFTl,  Millipore
Corporations, Burlington MA) and then stained with Sato
modified lead stain for 7 min and washed as above. Grids were
examined with an FEI Technai T20 Biotwin transmission
electron  microscope  and  images  collected  with  a  high-
resolution thermoelectrically cooled Gatan Orius dual-scan
CCD camera (Gatan, Inc.; Warrendale, PA).
Whole-genome association study:
Group design—Nineteen crd3-affected purebred GIT
dogs were selected that were the least related to each other as
possible, based on maximizing the number of grandparents
contributing to the selected cases. Two GIT-derived, mixed-
breed crd3-affected dogs were added to bring the total number
of cases to 21. A total of 22 unaffected purebred GIT dogs
were similarly selected as the least related to each other, but
matched pairwise to the affected dogs (i.e., siblings or parents
of affecteds).
Single  nucleotide  polymorphism  genotyping—
Samples were genotyped using Affymetrix Version 2 Canine
single nucleotide polymorphism (SNP) chips and the standard
Affymetrix  GeneChip  Mapping  250K  Sty  Assay  protocol
(Affymetrix Inc., Santa Clara, CA), using 250 ng genomic
DNA. Genotypes were called using the MAGIC algorithm
[13] on batched sets of the Affymetrix probe results files (CEL
files).
Association analysis—Genotype calls were tested for
association with disease phenotype using Fisher’s exact test
to test for under/over-representation of the disease phenotype
in one homozygote class versus the rest (i.e., versus a class
pooling  heterozygotes  with  homozygotes  for  the  opposite
allele). This test was done twice, pooling heterozygotes with
either  homozygote  in  turn.  A  Bonferroni  correction  for
multiple tests was used to set the genome-wide significance
threshold at -Log10(p)≥6.39 [0.05/(60,245*2)]. Genotype calls
for  chromosome  16  were  assembled  into  haplotypes  to
identify the minimal linkage disequilibrium (LD) interval.
Candidate genes evaluation: Candidate-gene screening was
done by exon scanning (Table 2). ADAM9 evaluation was
done by amplification of overlapping fragments covering the
complete coding region of the gene (Table 3), from normal
and affected retinal cDNA (12 weeks and 13.4 weeks old,
respectively)  prepared  with  Reverse  Trancriptase  enzyme
(ThermoScript, Invitrogen, Carlsbad, CA) and 2 μg retinal
RNA following the manufacturer’s protocol. Twenty ng of
DNA or cDNA was denatured at 95 °C for 2 min, and 35 cycles
of 95 °C for 30 s, 58 °C for 30 s, and 72 °C for 1 min/1000 bp
were performed in a thermal cycler (MJ Research, Watertown,
MA). An additional final extension time of 5 min at 72 °C
ensured full-length products. When necessary, PCRs were
optimized by increasing the annealing temperature to up to
64 °C. The reactions were performed using GoTaq® Green
Master Mix (Promega, Madison, WI) in a final volume of
25 μl. PCR products were run on 1.8% agarose and stained
with  ethidium  bromide  (2  μg/ml  in  a  water  bath).  Single
specific PCR products were extracted using the Qiagen PCR
extraction kit (Qiagen) and eluted in 10 mM Tris–HCl (pH
7.5).  Some  products  were  extracted  from  the  gel  using  a
Qiagen gel extraction kit (Qiagen). A PCR product (200 ng/
1000 bp) was mixed with 8 pmol of, either forward or reverse
primer, and sequencing was performed using the Applied
Biosystems  Automated  3730  DNA  analyzer  (Applied
Biosystems,  Foster  City,  CA).  Each  PCR  product  was
sequenced with the forward and reverse primer. Sequences
were then analyzed and compared using Sequencher 4.2.2
software (Gene Codes Corp., Ann Arbor, MI).
ADAM9  mutation  identification:  To  further  characterize
canine ADAM9, 33 primer pairs were designed to amplify and
sequence the genomic interval between exon 14 and exon 17
from one normal and two affected dogs (Table 4).
Mutation screening: To identify crd3-affected, -carrier, and -
normal dogs, a multiplex PCR was designed to amplify the
normal and mutated alleles in one PCR reaction. One primer
pair, specific to the normal allele, was located within the
deleted sequence, and one primer pair specific to the mutant
allele flanked the deletion.
RNA expression: RNA was extracted from a 13.4-weeks-old
crd3-affected retina and from 8.6-, 10.4-, and 12-weeks-old
normal retinas, as well as 7.7- and 15.7-weeks-old normal
brains and a 22.1-weeks-old normal spleen. For Northern
analysis,  10  μg  of  total  RNA  was  mixed  with  10  μg/ml
ethidium bromide and 3X gel loading buffer (Ambion, Austin,
TX) in a final volume of 10 μl, heated at 65 °C for 10 min,
chilled on ice for 2–3 min, and loaded on a 1% agarose-
formaldehyde denaturing gel; 3 μg of 0.24–9.5 kb RNA ladder
was used as a size marker (Invitrogen). The gel ran with
continuously circulating 1X Mops running buffer (Ambion)
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1557for 16 h at 21 V. After three 5-min washes in DEPC-treated
water, 20 min in 0.05 N NaOH, and a 15-min soak in 10X
SSC, transfer to a nylon-based membrane (GeneScreen Plus;
NEN Life Science, Boston, MA) was done with 10X SSC
buffer using a standard protocol. Full transfer was confirmed
by exposing the gel to UV light. The membrane was washed
in  2X  SSC  for  2  min,  and  RNA  was  cross-linked  to  the
membrane  (exposure  was  0.12  J/cm2;  Stratalinker  UV
Crosslinker; Stratagene, La Jolla, CA). An ADAM9 probe
was produced by amplification of normal retinal cDNA using
primers located on the 5′ UTR and exon 6, to produce a probe
610 bp long. The product was then cloned (TOPO TA cloning
kit, Invitrogen), and the probe was labeled with [α-32P]dCTP
using  a  RadPrime  DNA  Labeling  System  (Invitrogen)
according to the manufacturer's protocol, then used for blot
hybridization. Hybridization was performed using Ultrahyb
solution (Ambion, Austin, TX) following the manufacturer’s
protocol, and the blot was exposed to X-ray film at −70 °C for
4 day with two intensifying screens. Loading control was
achieved by hybridizing a canine-specific beta-actin probe to
the membranes under the same conditions and exposing it to
X-ray film for 2 h.
RESULTS
Phenotypic evaluation: Clinically, GIT dogs affected by crd3
were diagnosable by ophthalmoscopic examination as young
as 3 years of age, although some affected dogs did not show
lesions until much older. With one exception, none of the dogs
diagnosed as clinically non-affected when examined at ages
over 8 years have since proven to be homozygous for the
ADAM9 mutation. The exceptional case was a 10 years-old
GIT that presented with an unusual geographic pattern of
pigmentary disturbance in the fundus of both eyes, but with
no  overt  evidence  of  the  retinal  thinning  or  vascular
attenuation expected in a crd3-affected dog of this age. Other
than this dog, disease was recognized ophthalmoscopically in
all  crd3-affected  dogs  by  5  years  of  age.  Two  distinctly
different clinical phenotypes, however, were observed. In the
majority of cases, disease first became apparent as a subtle but
generalized alteration in the fundus, as is typically seen in
many other forms of late-onset hereditary retinal degeneration
in  dogs.  In  these  cases,  subtle  but  generalized
hyperreflectivity of the tapetal fundus, and retinal vascular
attenuation, were the predominant signs of early disease, and
these changes worsened appreciably within 12–24 months of
initial  observation.  In  a  minority  of  cases,  the  initial
ophthalmoscopic change detected was confined to the area
centralis  (mid-temporal  tapetal  fundus),  as  a  discrete,
distinctly  hyperreflective  lesion,  with  no  accompanying
ophthalmoscopic evidence of generalized retinal disease. In
these dogs, the central lesion remained unchanged for at least
12 months after initial detection, but over a longer period (2–
4  years),  it  did  eventually  progress  to  generalized  retinal
involvement.
The electroretinogram (ERG) of a 12-weeks-old, crd3-
affected dog (Figure 1B) was indistinguishable from normal
(Figure  1A),  showing  normal  rod-  and  cone-mediated
responses to light stimuli. At about 15 months of age, ERG
dysfunction  was  detected  as  reduced  30  Hz  cone  flicker
responses  (Figure  1C),  and  at  later  ages  by  continued
deterioration of both cone and rod responses (Figure 1D,E).
At all ages, the loss of cone function was more marked than
that of rods, hence the designation of the disorder as a cone-
rod dystrophy.
Morphology: By light microscopy, at 4.7 weeks of age, the
rod and cone inner (IS) and outer segments (OS) of the crd3-
affected  retina  lacked  the  tightly  packed,  highly  parallel
organization of a normal photoreceptor layer (Figure 2). At
4.7, 13.4, and 18 weeks of age (Figure 2B,C,D), an apparent
gap was consistently observed between the distal ends of the
Figure 1. Electroretinograms of normal and affected dogs. Electroretinograms (ERGs) from a 7 weeks old normal dog (A), a 12 weeks old
dog affected with canine cone-rod dystrophy 3 (crd3; B), a crd3-affected dog aged 1.2 years (C), a 2 years old crd3-affected dog (D), and a
4.9 years old crd3-affected dog (E). Each vertical panel presents electroretinogram (ERG) responses to a red flash, a blue flash, a white flash,
5 Hz low-intensity white flashes (Rod), and 30 Hz high-intensity white light flicker (Cone). Short vertical arrows under the Rod and Cone
flicker responses indicate the onset of the flickering light stimuli. Red and White traces represent mixed rod-cone responses, Blue and Rod
traces are rod-specific, and Cone traces are cone-specific. Responses of the 12-weeks-old crd3-affected dog appear normal (B), but by 15
months of age, cone dysfunction is detected as reduced 30 Hz flicker responses (C), and is followed at later ages by continued deterioration
of both cone and rod responses (D, E). At all ages, the loss of cone function is more prominent than that of rods. Vertical calibration bar=100
µV; horizontal=200 ms for rod flicker; and other responses are 100 ms.
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1558photoreceptor OS and the retinal pigment epithelium (RPE;
Figure  2D,  arrows);  IS  and  OS  appeared  disarrayed  and
disorganized; and structural abnormalities of cone IS and OS
were at least as or more severe than those of rods. At later
ages, distinct thinning and reduction of cell numbers in the
ONL was observed (Figure 2 E,F). At 5 years of age (Figure
2F), cones and rods were severely reduced in number, with
only  a  few  nuclei  remaining  in  the  ONL,  most  of  which
appeared rod-like.
By electron microscopy, in the crd3-affected retina, the
apical microvilli of the RPE showed very little of the normal
investiture of rod and cone outer segments (Figure 2 H,I).
Mostly these microvilli formed a flattened, entangled mat
between the RPE cell bodies and the distal OS tips of the
Figure 2. Light- and electron-microscopic retinal morphology in normal and canine cone-rod dystrophy 3 (crd3) affected dogs. In the retina
of a 27-weeks-old non-affected dog (A), the outer nuclear layer (ONL) comprises approximately 10 rows of rod nuclei and a single distal row
of cone nuclei. The inner and outer segments of the photoreceptors (IS, OS) are of consistent proportions, tightly aligned, and parallel, and
the distal OS tips are in close proximity to the apical membrane of the retinal pigment epithelium (RPE). In retinas of 4.7- and 13.4-weeks-
old crd3-affected dogs (B, C), rod and cone IS and OS lack the tightly packed highly parallel organization of a normal photoreceptor layer,
and the distal OS tips appear to be more distant from the RPE apical membrane than in normal dogs. In the retina of an 18-weeks-old crd3-
affected dog (D), IS and OS are disarrayed and disorganized, and a distinct gap is observed between the RPE and the OS (arrows). The retinas
of 26-weeks- and 5 years-old crd3-affected dogs (E, F) exhibit continued photoreceptor degeneration as evidenced by loss of cone and rod
IS, OS, and nuclei. Electron micrograph of the retina of a 27-weeks-old nonaffected dog (G) shows that the microvilli from the RPE apical
membrane extend to invest the photoreceptor OS. Electron micrographs of the retina of a 13.4-weeks-old crd3-affected dog (H, I) show that
the RPE apical microvilli form a tangled flattened mat that does not extend to invest the photoreceptor OS (arrows).
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1559photoreceptors. This mat appeared to correspond to the gap
seen between the RPE and the OSL by light microscopy.
Whole-genome association analysis: Of the approximately
127,000 loci represented on the Affymetrix vs2 SNP chip,
60,245  passed  the  quality  control  incorporated  into  the
MAGIC algorithm. One affected sample was contaminated
and  was  excluded  from  the  analysis.  Comparison  of  two
duplicated samples, to assess the consistency of the MAGIC
program, found 98.4% of the calls to be identical in the first
duplicate, and 93.3% in the second duplicate, for an average
of  95.8%,  and  most  mismatched  calls  were  between  an
unclustered call and a defined call.
Fisher Exact analysis, comparing genotypes of cases to
controls, identified an association signal on CFA16 (Figure 3)
extending over 6 Mb and including 28 SNPs that exceeded the
Bonferroni  corrected  significance  threshold  (-Log10(p)
range=6.39–10.09,  Table  5).  The  peak  p-value  (-
Log10(p)=10.09)  was  shared  by  six  SNPs  comprising  an
interval  of  approximately  4.4  Mb  (CFA16:  22,690,750–
27,122,415). All affected dogs were homozygous at these
SNP loci, suggesting a recessive mode of inheritance. With
that in mind, all genotype calls on CFA16 were aligned to
identify a homozygosity block, that is, where all genotype
calls  for  all  affected  dogs  were  homozygous,  between
Figure 3. Results of genome-wide association study in canine cone-rod dystrophy 3. The statistical signal (y-axis, negative Log10 [Fisher
exact test 2-tailed probability]) for association between canine single-nucleotide polymorphism (SNP) genotype and canine cone-rod dystrophy
3 (crd3) phenotype, plotted against SNP chromosomal location (A), demonstrates a distinct peak on canine chromosome 16 (CFA16). Green
dots are SNPs for which the association signal exceeded the Bonferroni threshold for genome-wide significance. Chromosome X is represented
by the numbers 39 and 40. Homozygosity analysis of SNP genotypes (B), in the region of CFA16 yielding the peak association signal, reveals
heterozygosity throughout the interval in 21 nonaffected control dogs, and demonstrates a 2.74 Mb homozygosity block in 20 crd3-affected
dogs. Genotypes are color coded as follows: pink and green represent the major and minor genotypes observed in affecteds, respectively;
yellow is heterozygous; and white is missing data. Black lines border the 2.74 Mb homozygosity block. Refseq genes screened as potential
positional candidates for crd3 in the present study (arrowheads), and ADAM family genes identified within the crd3 minimal linkage
disequilibrium interval (arrows) are indicated with annotation and order consistent with the CanFam2 canine genome assembly (C, not drawn
to scale).
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1560positions  27,854,074  and  30,597,700–a  2.74  Mb  interval
(Figure 3; Appendix 1). The block of homozygosity was not
observed in controls except for one dog (dog number 17 in
Appendix 1). This dog, when first examined at 10 years of
age, had retinal lesions that were regarded as incompatible
with a diagnosis of crd3, but in retrospect were likely to
represent an unusually delayed and mild form of crd3 disease.
Thus,  this  homozygosity  block  represents  the  region  of
absolute  linkage  disequilibrium  (LD)  of  crd3  in  the  GIT
population examined
Homozygosity analysis: To evaluate the power of association
mapping by homozygosity, we analyzed genotype calls from
just the 20 affected dogs (59,408 SNP calls from autosomal
chromosomes) to identify homozygosity blocks greater than
1.0 Mb. Five such blocks were identified where all 20 affected
dogs were homozygous for the same allele, and 10 blocks
where 19 of the 20 were homozygous for the same allele
(Table 6).
Candidate gene screening: The crd3 minimal LD interval
(CFA16:  27,854,074  -  30,597,700)  was  identified  as
homologous to part of human chromosome 8p11, although the
gene order is rearranged between human and dog (data not
shown).  Although  CORD9,  a  human  autosomal  recessive
cone-rod  dystrophy,  had  previously  been  mapped  to  this
human  interval  [14],  the  CORD9  gene  had  not  yet  been
identified at the time of the current study. Comparison of
genes common to the CORD9 mapped interval and the crd3
LD interval identified 31 potential candidate genes. Ten of
these were completely screened (chromosome 8 open reading
frame 4 [C8orf4], indoleamine 2,3-dioxygenase 1 [IDO1],
TM2 domain containing 2 [TM2D2], leucine zipper-EF-hand
containing transmembrane protein 2 [LETM2], phosphatidic
acid  phosphatase  type  2  domain  containing  1B
TABLE 5. GENOME WIDE ASSOCIATION STUDY RESULTS
  A. Sort by -Log10(p) B. Sort by location
Number Location -Log10(p) Location -Log10(p)
1 28600467 10.09 25601422 6.39
2 28926606 10.09 27844483 7.76
3 29299541 10.09 27845657 8.88
4 30342464 10.09 27854074 7.76
5 30480010 10.09 28286469 9.34
6 29748980 10.09 28301327 9.03
7 28286469 9.34 28592790 9.03
8 30509498 9.34 28600467 10.09
9 28301327 9.03 28926606 10.09
10 28592790 9.03 29299541 10.09
11 27845657 8.88 29495970 8.16
12 29949196 8.46 29543182 8.16
13 29967119 8.46 29748980 10.09
14 30022978 8.46 29949196 8.46
15 30031243 8.46 29967119 8.46
16 30348569 8.19 30022978 8.46
17 29495970 8.16 30031243 8.46
18 29543182 8.16 30039251 7.67
19 31638702 8.12 30342464 10.09
20 30473690 7.93 30348569 8.19
21 27844483 7.76 30473690 7.93
22 27854074 7.76 30480010 10.09
23 30039251 7.67 30509498 9.34
24 31810810 7.28 31638702 8.12
25 31664333 6.97 31664333 6.97
26 31793958 6.97 31793958 6.97
27 31823035 6.61 31810810 7.28
28 25601422 6.39 31823035 6.61
Single Nucleotide Polymorphisms that passed Bonferroni correction, location on chromosome 16, and -Log10(p) values  sort by
-Log10(p) values (A) and by location (B). Bolded are the single nucleotide polymorphisms (SNPs) with the highest -Log10(p)
values.
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1561[PPAPDC1B],  DDHD  domain  containing  2  [DDHD2],
LSM1  homolog,  U6  small  nuclear  RNA  associated  (S.
cerevisiae) [LSM1], steroidogenic acute regulatory protein
[STAR], eukaryotic translation initiation factor 4E binding
protein  1  [EIF4EBP1],  and  ER  lipid  raft  associated  2
[ERLIN2])  and  three  (HtrA  serine  peptidase  4  [HTRA4],
BRF2, subunit of RNA polymerase III transcription initiation
factor, BRF1-like [BRF2], and G protein-coupled receptor
124 [GPR124]) were partially screened, by exon scanning
(Figure 2C; Table 2). All 10 were excluded from association
with crd3.
ADAM9  evaluation:  When  a  mutation  in  ADAM9  was
established as associated with CORD9 [9], we evaluated its
role  in  crd3-affected  dogs.  The  human  ADAM9  gene
(NM_003816.2) has 22 exons and encodes an 819-amino acid
protein. Blasting this sequence against CanFam2 identified 21
of  the  predicted  canine  exons  but  failed  to  identify  the
complete sequence of exon 4. This sequence was identified
completely in the CanFam1 assembly. Six primer pairs were
designed from CanFam2 to amplify overlapping retinal cDNA
fragments of the complete canine ADAM9 coding sequence
(Table 3, primer pairs 1 to 6). From normal retinas, all six
primer-pairs each amplified a single product and alignment of
the  overlapping  sequences  established  a  2,781  bp  canine
ADAM9  cDNA  sequence  (accession  number  HM590630)
comprising 29 bp of 5′ UTR, 2,460 bp of coding region, and
292 bp of 3′ UTR.
From affected retinas, primer pairs 4 (exon 13 to 16) and
5  (exon  16  to  22)  both  failed  to  amplify  a  product.
Subsequently, amplification with primer pair 7 (exon 14 to
18) gave 573 bp and 283 bp product from normal and affected
dogs, respectively. Primer pair 8 (exon 15 to 18) failed to
amplify cDNA from the affected dog, but yielded a 389 bp
product from normal dogs. Sequence analysis of the 283 bp
crd3-affected amplicon from primer pair 7 showed that exons
15 and 16 are absent from affected cDNA.
The genomic interval between exon 14 and exon 16 was
partially amplified and sequenced from one normal and two
affected dogs (Table 4). This interval spans over 40 Kb in
CanFam2  (CFA16:  29,384,764–29,425,539).  Initial
screening used 25 primer pairs, evenly distributed (Table 4).
Primer pairs 3 to 16 failed to amplify DNA in the two affected
dogs. This suggested a deletion of at least 21 Kb, between
intron 14 and intron 16. To refine the deletion points, PCR
was done using an additional eight primer pairs, amplifying
overlapping  fragments  (Table  4,  F26/R26–F33/R33).
Surprisingly, all eight primer pairs amplified fragments from
the affected dog that were identical in size to those from the
normal dog. Critical examination of the CanFam2 sequence
revealed  an  LTR  sequence  in  intron  14  (29,422,135–
29,423,412)  and  another  in  intron  16  (29,398,914–
29,400,191), with 99.5% identity (6 SNPs in 1,278 bp). That
suggested that unbalanced recombination between the two
LTRs  might  have  led  to  a  deletion  of  more  than  23  Kb,
resulting in a single fused copy of the LTR and deletion of
exon 15 and 16 from the genome (Figure 4A). To test this
hypothesis, PCR was undertaken with primers F29 (on intron
14, upstream from the first LTR) and R31 (on intron 16,
downstream from the second LTR). This distance is >24 Kb
in the normal genomic DNA, and in the proposed scenario
should be only 1,515 bp in the affected dogs. The PCR failed
to  amplify  DNA  in  the  normal  dog,  and  amplified  the
predicted size product from affected ones. The sequence of
this product revealed a deletion of 23,221 bp between the LTR
in intron 14 and the LTR in intron 16. This deletion included
part of intron 14, all of exon 15, intron 15 and exon 16, and
part of intron 16. The SNPs in the LTRs suggest that the
unbalanced recombination took place between the first and
TABLE 6. HOMOZYGOSITY EVALUATION.
Chromosome Size of block >1.0 Mb
  19/20 dogs homozygous to same allele 20/20 dogs homozygous to same allele
1 1.02 -
12 1.25 -
12 3.57 -
12 1.19 -
14 1.4 1.4
16 3.14 2.74
20 1.26 1.26
21 1.94 1.94
26 1.33 1.33
38 1.2 -
Total 10 5
Homozygosity analysis was done on genotype calls for crd3- affected dogs (n=20). Blocks of homozygosity for the same allele
were  measured, and those greater than 1.0 Mb were recorded. In bold is the homozygosity block that bears the mutation for
crd3.
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1562the second of these SNPs, and resulted in a chimeric, single
LTR (Figure 4A).
Population mutation screening: Multiplex PCR was designed
to amplify the normal and mutated alleles of canine ADAM9
Figure 4. ADAM9 mutation in canine cone-rod dystrophy 3 (crd3) affected dogs. A schematic drawing, of part of the canine ADAM9 genomic
sequence, aligning the normal and crd3 mutant alleles suggests a possible mutation mechanism. Bordered square boxes represent exons 14–
17, lines between are introns; unbordered rectangular boxes represent long-terminal repeat sequences (LTR). Within the LTR are the
nucleotides identified as single nucleotide polymorphisms (SNPs). A suggested mechanism of unbalanced recombination is illustrated,
resulting in the deletion of part of intron 14, all of exon 15, intron 15, exon 16, and part of intron 16, as well as the formation of a single
chimeric LTR. Arrows represent the location of primers used to identify the mutation. Primer pair F29/R31 amplifies the mutant allele and
results in a 1,515 bp PCR product from genomic DNA. Primer pair F10/R10 amplifies the normal allele and results in a 602 bp PCR product
from genomic DNA. B: Gel electrophoresis of multiplex PCR reaction identifies ADAM9 alleles from normal (N), crd3-carrier (C), and crd3-
affected (A) dogs. The lower, 602 bp band is the normal allele, amplified by primer pair F10/R10 located within intron 15, which is deleted
in the affected allele. The upper 1,515 bp band is the mutant allele, amplified by primer pair F29/R31, which flanks the >23 kb sequence
deleted in the affecteds. Both bands are present in the heterozygous carrier dog. The normal and crd3 mutant canine ADAM9 transcripts, and
their corresponding predicted translation products, are aligned (C) to illustrate their differences schematically. The protein domains represented
are those predicted by Swiss-Prot for the human ADAM9 protein. Exons 15 and 16 are missing from the mutant transcript, and a premature
stop codon is introduced (arrow). The mutant protein translated from this transcript is predicted to be truncated, lacking the last 287 amino
acids of the C-terminus, part of the cysteine-rich domain, the complete epidermal growth factor (EGF)-like domain, the transmembrane domain,
and the cytoplasmic tail.
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1563(Table 7, Figure 4A,B). Primer pair 10F/10R, located within
intron 15, will only amplify a 602 bp-long fragment from a
normal chromosome. The affected allele is detected using
primers F29/R31, which flank the deletion. All dogs included
in the GWAS were genotyped. All 20 affected dogs were
homozygous for the mutation; five control dogs were carriers
(dogs 7, 9, 10, 12, and 13 in Appendix 1, of which 10 and 13
were obligate heterozygotes because they produced affected
dogs); and 16 controls were homozygous normal. Dog number
17 in the control group, whose genotype in the minimal LD
region was identical to that of affected dogs, was homozygous
for the mutation, confirming this dog’s affected status.
Thirty-six further purebred GIT dogs, not part of the
GWAS, were screened for the mutation. Ten of these that had
been  diagnosed  as  affected  were  homozygous  for  the
mutation;  24  non-affected  dogs  were  either  homozygous
normal, or heterozygous; and two dogs that were clinically
non-affected when examined at young ages (1.2 and 2 years
old) were homozygous for the mutation, and presumably will
become affected at a later age. A subset of crd3-colony dogs
was  genotyped  as  well,  and  showed  segregation  of  the
ADAM9 mutation with the disease (data not shown). The
ADAM9 mutant allele was not found in 80 dogs from 16 other
different breeds (Table 1).
The association between the six most significant SNPs
identified from the GWAS was further analyzed by comparing
the genotype for each SNP with that at the ADAM9 mutant
locus, and calculating the correlation coefficients. Two SNPs
(rs22468640 and rs22463503, located 798 Kb and 472 Kb
upstream from the mutation, respectively) were in complete
linkage disequilibrium with the mutation, with r=1, while the
other four had correlation coefficients between 0.929 and
0.976 (data not shown).
ADAM9 mutation: in silico protein analysis: The 2,781 bp
canine  ADAM9  mRNA  (accession  number  HM590630,
Appendix 2) is predicted to encode an 819-amino acid protein,
and  comparison  to  the  human  ADAM9  protein  database
(Swiss-Prot)  suggests  that  this  protein  includes  a  signal
peptide (amino acids 1–28, translated from exon 1); a pro-
domain  (amino  acids  29–211,  exon  2–exon  7);  a
metalloprotease domain (amino acids 212–404, exon 7-exon
12); a disintegrin domain (amino acids 414–501, exon 12-
exon 14); a cysteine-rich domain (amino acids 505–634, exon
14-exon 17); an EGF-like domain (amino acids 644–698,
exon 17-exon 19); and a transmembrane domain (amino acids
698–718, exon 19). Amino acids 29–697 are extracellular,
698–718  are  transmembrane,  and  719–819  represent  the
cytoplasmic tail (Figure 4C; Appendix 2).
Amplification of the ADAM9 coding region from crd3-
affected  retina  identified  a  2,491  bp-long,  transcript  that
included all exons except 15 and 16, which are deleted from
genomic DNA (Appendix 2). The mutation causes a frame
shift, and results in a premature stop codon at base number 6
of exon 17. The mutant protein translated from this transcript
is predicted to be truncated and to lack the last 287 amino acids
of the C-terminus. That would remove part of the cysteine-
rich  domain,  the  complete  EGF-like  domain,  the
transmembrane domain, and the cytoplasmic tail (Figure 4C;
Appendix 2).
RNA  expression  profile:  Full-length  RNA  expression  was
evaluated by northern blot assay to determine the ADAM9
mRNA transcript size and absolute level of expression in crd3-
affected  retinas,  compared  to  normal  ones.  Northern  blot
analysis  showed  one  transcript  of  about  4.0  Kb,  highly
expressed in non-affected retinas, and in lower levels in the
brain and spleen (Figure 5). In the affected retinas, a smaller-
size band was observed, which corresponded to the mutated
allele, and the level of expression seemed slightly reduced,
compared to normal.
DISCUSSION
Recent  advances  in  canine  genomics  have  increasingly
highlighted and exploited the wealth of hereditary traits that
the  domesticated  dog  provides.  Such  traits  range  from
morphology  and  behavior,  through  a  panoply  of  genetic
diseases and disease susceptibilities, and extend to broader
aspects of population and genomic evolution [15–19]. One
specific and highly productive focus within this broader field
has been into the numerous hereditary retinal diseases that
segregate in specific canine populations. Numerous genes
causally  associated  with  these  retinal  diseases  have  been
identified [20,21] providing novel insights into the structural
and functional mechanisms involved in normal and diseased
retinas  [22],  and  a  suite  of  canine  models  for  preclinical
TABLE 7. GENOMIC PCR PRIMERS. PRIMER PAIRS, SEQUENCES, LOCATION AND OBSERVED PRODUCT SIZES IN NORMAL, CRD3-CARRIER, AND CRD3-AFFECTED DNA, USED IN
MULTIPLEX ANALYSIS. NO=NOT OBSERVED.
Primer
pair
Forward
primer
name
Forward primer
sequence
Forward
primer
location
Reverse
primer
name
Reverse primer
sequence
Reverse
primer
location
Observed
size from
normal dog
(bp)
Observed
size from
crd3-
carrier
dog (bp)
Observed
size from
crd3-
affected
dog (bp)
1 F10 tctaaaatggaggaagtgtg
aactaca
Intron 15 R10 ttcttggcttgggctaactct Intron 15 602 602 NO
2 F29 ctggagcaatggggctgga
ta
Intron 14 R31 tcaaaggagcaatcggaaa
agtct
Intron 16 NO (>24 Kb) 1515 1515
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1564evaluation  of  potential  therapies  for  comparable  human
diseases [23–26].
Canine population structure comprises multiple discrete,
essentially closed populations; the specific breeds of dog lend
themselves to genetic studies in much the same way as do the
isolated human populations that geneticists have appreciated
for many years [27–30]. Genome-wide association studies
(GWAS) of Mendelian and complex traits in isolated human
populations typically use platforms yielding genotypes for
more  than  500,000  informative  SNPs  [31–33].  GWAS
efficiency is facilitated by the large LD blocks in these human
isolate  populations.  In  particular,  young  isolates  with
relatively few founders show particularly extensive LD with
few gaps [31].
The  division  of  the  canine  population  structure  into
multiply isolated subsets, each of fairly recent origin and
characterized  by  significant  inbreeding  and  a  restricted
number of founders, permits a GWAS to be undertaken with
a relatively lower number of cases and controls, and a much
less dense set of SNP loci [6,7,32–35] than has typically been
needed in human populations. In the present study, a GWAS
identified the locus responsible for cone-rod dystrophy in the
Glen of Imaal Terriers (crd3), using a carefully selected set of
20  affected  and  22  non-affected  dogs.  Evaluation  of  a
homozygosity approach suggested that just genotyping a large
group  of  affected  dogs  could  be  adopted  in  autosomal
recessive diseases, where the tradeoff for using fewer samples
comes  in  the  form  of  a  few  false  positive  regions  of
homozygosity. Nonetheless, this could be useful where the
availability of cases and controls is severely restricted.
Positional candidate gene analysis identified a 23,221 bp
deletion within the canine ADAM9 gene, leading to a loss of
exons 15 and 16, a premature stop codon, and a predicted
protein truncated at its c-terminus. This establishes crd3 as a
true  ortholog  of  human  CORD9,  in  which  four  distinct
ADAM9 mutations have been found [9]. The latter mutations
are  either  nonsense  mutations  or  frame-shift  mutations
leading to nonsense change, all within the pro-domain or the
metalloprotease domain. The canine mutation resembles the
human in that it causes a frame-shift and a nonsense change,
which would lead to a truncated protein.
Initially, the Adam9−/− mouse was reported as having no
evident major abnormalities during development or adult life
[36],  but  subsequent  reevaluation  identified
electroretinographic abnormalities, suggesting a progressive
degeneration  affecting  both  rods  and  cones  [9].
Histologically, the retinas of these mice showed an abnormal
gap between the photoreceptor outer segment distal tips and
the  RPE  apical  membrane,  which  electron  microscopy
revealed to be a failure of the RPE apical processes to invest
the OS; instead, they formed a flattened distorted mat between
the OS and the RPE [9].
The light microscopic and ultrastructural morphological
abnormalities of crd3-affected canine retinas reported herein
are clearly consistent with those observed by Parry et al. in
the  Adam9−/−  mouse  [9].  As  in  the  mouse,  the  canine
ADAM9 mutant retina exhibits disarray, disorganization, and
progressive degeneration of the photoreceptors. Unique to
these two orthologous diseases, and presumptively therefore
involved  in  human  CORD9,  is  the  failure  of  RPE  apical
microvilli to invest the photoreceptors. This strongly suggests
that this structural abnormality reflects the absence of a critical
function served by ADAM9.
Figure  5.  ADAM9  RNA  expression
profile  in  normal  and  crd3-affected
retinas. Northern blot, RNA expression
of ADAM9 in frontal lobe, brain of 15.7
weeks-old normal dog (Lane 1); brain of
7.7  weeks-old  normal  dog  (Lane  2);
retina  of  10.4-weeks  old  normal  dog
(Lane 3); retina of 8.6-weeks old normal
dog (Lane 4); spleen of 22.1-weeks-old
normal dog (Lane 5); retina of 12-weeks
old normal dog (Lane 6); and retina of
13.4-weeks-old  crd3-affected  dog
(Lane 7). A single band is observed at
approximately 4.0 Kb. ADAM9 is highly
expressed in retinas not affected with
crd3 (lanes 3, 4, and 6), and at lower
levels in brain and spleen (lanes 1, 2, and
5). In crd3-affected retina (lane 7), the
mutant allele is observed as a slightly
smaller band, and its level of expression
appears  slightly  reduced  compared  to
the normal.
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1565ADAM  proteases  form  a  still-growing  family  of
transmembrane  proteins.  The  human  genome  contains  25
ADAM  genes,  of  which  four  appear  to  be  pseudo-genes
(ADAM1,  ADAM3,  ADAM5,  and  ADAM6)  and  nine  are
expressed  in  the  retina  (ADAM9,  ADAM10,  ADAM11,
ADAM12,  ADAM15,  ADAM17,  ADAM19,  ADAM23,  and
ADAM33; UniGene). In contrast, the mouse and rat have 37
and  34  ADAM  genes,  respectively,  many  of  which  are
specifically expressed in testis. In the canine genome, 30
ADAM genes are predicted (Genome), with the five additional
genes,  compared  to  human,  apparently  corresponding  to
mouse genes specifically expressed in testis. Most of the genes
in this family lack a functional protease domain, and appear
to code primarily for adhesion proteins. ADAM9 is one of a
few that have both adhesion and proteolysis functions [37–
39]. Most ADAMs feature a significant overlap of substrate
specificities,  which  may  explain  why  inactivation  of
individual  ADAMs  only  rarely  causes  major  phenotypes.
With that said, careful evaluation is needed, as the phenotype
alteration is sometimes overlooked [36].
Comparison of the predicted canine, human, and mouse
ADAM9 proteins shows that the human and canine sequences
are more similar to each other than are human and mouse
sequences (92.6% and 78.4%, respectively). The differences
reside  predominantly  in  the  cytoplasmic  tail,  where  only
14.7% of the mouse amino acids are identical to the human,
compared  to  a  93.1%  identity  for  dog  amino  acids.
Furthermore, the mouse cytoplasmic tail has 26 additional
residues that are absent from both the human and canine
proteins.
Identification of this ADAM9 mutation in crd3 provides
a  potentially  important  canine  model  for  CORD9.  The
opportunity  to  undertake  synergistic  studies  among
orthologous murine and canine models and human patients
has been very useful both for advancing knowledge of the
disease mechanism in numerous disorders and for developing
potential therapies. CORD9-affected human patients suffer
childhood-onset visual acuity impairment, progressing over
decades to major loss of central and then peripheral visual
function [14]. Thus, disease severity clearly establishes a basis
for considering genetic therapy. In the canine model, the retina
is not fully developed until 8 weeks of age, the cone and rods
are largely intact as late as 12 weeks postnatally, and the ERG
shows normal responses up to one year of age. Thus, there is
not only a prima facie case for therapeutic intervention based
on disease severity, but also a significantly long-term window
of opportunity.
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1568Appendix 1. Genotype calls from 20 crd3-affected cases and 22 control dogs,
in a 6.1 Mb interval on canine chromosome 16.
The interval includes all SNPs yielding an association
signal  exceeding  the  Bonferroni  corrected  threshold  for
genome wide significance. Columns=dogs, rows=SNP loci.
For each locus, homozygosity for the most frequent allele
observed in cases is color-coded in pink for all dogs (i.e., cases
and controls); green indicates homozygosity for the minor
allele observed in cases; yellow indicates heterozygosity; and
white (–)=no call. The crd3-absolute LD interval is boxed.
Control dog 17 proved to be affected with an atypical form of
crd3 (see text). To access the data, click or select the words
“Appendix 1.” This will initiate the download of a compressed
(pdf) archive that contains the file.
Appendix 2. Canine ADAM9 mRNA and predicted protein.
A. Canine ADAM9, normal allele. A1. ADAM9 mRNA
sequence  from  normal  dogs.  Upper  case  indicates  coding
sequence, boxed are the first methionine and the stop codon.
In bold are exons 15 and 16 that are missing in the affected
dog. A2. Canine ADAM9, predicted protein from a normal
dog. The protein is 819 amino- acids long. Features in the
protein are as follow: Red sequence: signal peptide- 1–28 aa
(translated  from  exon  1);  Grey  sequence:  29–211  aa
(translated  from  exon  2-  exon  7);  Orange  sequence:
Metalloprotease domain: 212–404 aa (translated from exon 7-
exon 12); Blue sequence: Disintegrin domain: 414–501 aa
(translated from exon 12-exon 14); Pink sequence: Cystein
rich domain: 505–634 aa (translated from exon 14-exon 17);
Brown sequence: EGF-like domain: 644–698 aa (translated
from exon 17-exon 19); Green sequence: Transmembrane
domain: 698–718 aa (translated from exon 19). Amino acids
29–697: extracellular, amino acids 698–718: transmembrane;
amino acids 719–819: cytoplasmic. B. Canine ADAM9, crd3
mutant allele. B1. Sequence of crd3 mutant canine ADAM9
mRNA. Boxed are the first methionine and the premature stop
codon. ◊ indicates the location of exons 15 and 16 missing in
the affecteds. Underlined is the stop codon in a normal dog.
B2.  Canine  ADAM9  predicted  mutant  protein  product.
Colored are the domains. The last two amino acids are not
present in the normal protein. The predicted protein is 532
amino- acid long. To access the data, click or select the words
“Appendix 2.” This will initiate the download of a compressed
(pdf) archive that contains the file.
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